ABCLAbCellera Biologics Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-27.2% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$93M-1276.2% margin

Net Income

-$37M-504.3% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-26.4%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$49M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$302M

Stockholders' Equity

$1.1B

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$10M	-27.2%
Gross Profit	$7M	$10M	-27.2%
Operating Income	-$93M	-$51M	-81.9%
Net Income	-$37M	-$31M	-21.0%

Revenue Segments

Research Fees

$5M74%

Milestone Payments

$2M20%

License

$370,0005%

ABCL Q2 2024 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena